Arvinas (NASDAQ:ARVN – Get Free Report) and Unicycive Therapeutics (NASDAQ:UNCY – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, institutional ownership, profitability, analyst recommendations, earnings and risk.
Profitability
This table compares Arvinas and Unicycive Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Arvinas | N/A | -50.26% | -24.87% |
| Unicycive Therapeutics | N/A | N/A | -29.88% |
Analyst Recommendations
This is a summary of current recommendations and price targets for Arvinas and Unicycive Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Arvinas | 0 | 1 | 14 | 0 | 2.93 |
| Unicycive Therapeutics | 0 | 0 | 4 | 1 | 3.20 |
Insider and Institutional Ownership
95.2% of Arvinas shares are owned by institutional investors. Comparatively, 40.4% of Unicycive Therapeutics shares are owned by institutional investors. 5.2% of Arvinas shares are owned by insiders. Comparatively, 24.1% of Unicycive Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Earnings & Valuation
This table compares Arvinas and Unicycive Therapeutics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Arvinas | $78.50 million | 16.62 | -$367.30 million | ($4.67) | -4.07 |
| Unicycive Therapeutics | $680,000.00 | 106.85 | -$30.54 million | ($0.97) | -0.72 |
Unicycive Therapeutics has lower revenue, but higher earnings than Arvinas. Arvinas is trading at a lower price-to-earnings ratio than Unicycive Therapeutics, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Arvinas has a beta of 1.82, indicating that its stock price is 82% more volatile than the S&P 500. Comparatively, Unicycive Therapeutics has a beta of 2.36, indicating that its stock price is 136% more volatile than the S&P 500.
Summary
Unicycive Therapeutics beats Arvinas on 10 of the 14 factors compared between the two stocks.
About Arvinas
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.
About Unicycive Therapeutics
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.
Receive News & Ratings for Arvinas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arvinas and related companies with MarketBeat.com's FREE daily email newsletter.
